Immunic, Inc. (NASDAQ:IMUX) Receives $11.60 Average PT from Analysts
Shares of Immunic, Inc. (NASDAQ:IMUX – Get Free Report) have been assigned a consensus recommendation of “Buy” from the eight brokerages that are covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price […]
Shares of Immunic, Inc. (NASDAQ:IMUX – Get Free Report) have been assigned a consensus recommendation of “Buy” from the eight brokerages that are covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price […]
